Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.76 USD
Change Today -0.10 / -3.50%
Volume 1.0M
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

cytrx corp (CYTR) Snapshot

Open
$2.85
Previous Close
$2.86
Day High
$2.87
Day Low
$2.72
52 Week High
04/21/15 - $5.42
52 Week Low
12/16/14 - $2.08
Market Cap
179.5M
Average Volume 10 Days
1.9M
EPS TTM
$-0.94
Shares Outstanding
65.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTRX CORP (CYTR)

Related News

No related news articles were found.

cytrx corp (CYTR) Related Businessweek News

No Related Businessweek News Found

cytrx corp (CYTR) Details

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. The company’s product candidate is aldoxorubicin, which is in Phase III clinical trial as a therapy for patients with soft tissue sarcomas (STS) whose tumors have progressed following treatment with chemotherapy; in Phase IIb clinical trial in small cell lung cancer; in Phase II clinical trial in HIV-related Kaposi's sarcoma; in Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); in Phase Ib trial in combination with ifosfamide in patients with soft tissue sarcoma; and in Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It also has completed Phase 2b and Phase 1b/2 clinical trials with aldoxorubicin as a first-line therapy for STS; a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors; and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. CytRx Corporation was founded in 1985 and is headquartered in Los Angeles, California.

26 Employees
Last Reported Date: 03/10/15
Founded in 1985

cytrx corp (CYTR) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.3M
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $450.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $825.0K
Senior Vice President of Drug Development
Total Annual Compensation: $650.0K
Senior Vice President of Legal Affairs, Gener...
Total Annual Compensation: $450.0K
Compensation as of Fiscal Year 2014.

cytrx corp (CYTR) Key Developments

CytRx Seeks Acquisitions

CytRx Corporation (NasdaqCM:CYTR) is seeking acquisitions. The net proceeds of the offering may be used to acquire additional product candidates or complementary assets or businesses.

CytRx Corporation Announces Encouraging Interim Data from Phase II Kaposi's Sarcoma Study

CytRx Corporation announced encouraging interim data from its ongoing open-label Phase II pilot study evaluating the efficacy and safety of aldoxorubicin for the treatment of Kaposi's sarcoma (KS), in HIV-infected patients. For the study, patients with biopsy-confirmed KS were administered 100 or 150 mg/m2 aldoxorubicin (75 or 112 mg/m2 doxorubicin equivalents) IV every three weeks. At the time of presentation, preliminary analyses were available for nine patients who received at least six cycles of drug (mean = 6.3 cycles). Four patients had received prior Doxil chemotherapy. Of these 9 patients, 6 (67%) demonstrated a partial response (PR) to aldoxorubicin at the end of study visit (EOS), and 7 (78%) demonstrated PR within 4 months of EOS. Doxorubicin could be detected in all tumor biopsies and higher doxorubicin concentrations were demonstrated within KS lesions relative to skin next to the lesions for 3/4 (75%) patients for whom adequate tissue was available for analysis. Five of 6 (83%) patients receiving aldoxorubicin and for whom data are available exhibited reduced intratumoral viral loads during therapy. A subset of patients also exhibited improvements in quality of life during treatment, and all patients exhibited either improvement or stability in immunologic and virologic HIV treatment parameters. Aldoxorubicin was well-tolerated, with only 2 patients (22%) experiencing a grade 4 adverse event (transient neutropenia and anemia), and overall AEs (44%) were mild and compared favorably with AE rates from other trials enrolling KS patients representing urban, minority-predominant populations. This open-label Phase II clinical trial is expected to enroll up to 30 patients, randomly assigned to two equally sized treatment arms which will receive aldoxorubicin at 100 or 150 mg/m2 by 30-minute intravenous infusion. Because the KS patients in the study have compromised immune systems, the aldoxorubicin dosages administered in the trial are lower than those administered in the Company's clinical testing of aldoxorubicin in patients with soft tissue sarcomas. Patients with advanced KS receive aldoxorubicin on day 1, then every 3 weeks until evidence of tumor progression, unacceptable toxicity or withdrawal of consent. The primary objectives of preliminary efficacy include evaluation of the size, number and nodularity of skin lesions, change in size and number of lung lesions and changes in the number of tumor cells that express viral DNA (Kaposi sarcoma-associated herpesvirus, the etiologic agent of KS). The company is also evaluating the level of aldoxorubicin uptake into lesions. Safety is being assessed through monitoring of adverse events and the ability to remain on assigned treatment. The trial is being conducted at the Louisiana State University Health Sciences Center in New Orleans, LA.

CytRx Corporation Unveils Linker Activated Drug Release Technology Platform

CytRx Corporation has unveiled its proprietary Linker Activated Drug Release, or LADR, technology platform. LADR is a discovery engine designed to leverage the company's expertise in albumin biology and linker technology for the development of a new class of anticancer therapies. Among the cancers being pursued are liver, pancreatic, and non-small cell lung cancer. "LADR is a creative, novel approach to the development of next-generation therapeutic drug conjugates, which have rationally designed to control release in tumors of high-potency chemotherapeutics that are attached to either albumin or anticancer antibodies With the first drug candidates from this platform expected to enter the clinic in 2016.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $2.76 USD -0.10

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies
 

Industry Analysis

CYTR

Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,593.7x
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,247.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTRX CORP, please visit www.cytrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.